Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03767335 · ClinicalTrials.gov registry record · Phase 1
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
A Phase 1 study, sponsored by Menarini Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT03767335 is a Phase 1 study that has completed, run by Menarini Group. The registered enrollment target is 62 participants.
The verdict
NCT03767335, a Phase 1 study, has completed, sponsored by Menarini Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer
Interventions
- DRUG Trastuzumab
- DRUG Fulvestrant
- DRUG MEN1611
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2024-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03767335
The ClinicalTrials.gov registry entry for NCT03767335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Menarini Group, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT03767335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03767335 about?
NCT03767335 is a clinical study titled "MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer". The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer
What is the current status of trial NCT03767335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2018-11-13. Estimated completion is 2024-02-23.
What interventions are being tested in trial NCT03767335?
The interventions under investigation include: Trastuzumab (DRUG), Fulvestrant (DRUG), MEN1611 (DRUG).
Who is sponsoring clinical trial NCT03767335?
This trial is sponsored by Menarini Group, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.